Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910884 | 1.00 | IDO1 (0.50) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL3858520 | 1.00 | IDO1 (0.50) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL30986701 | 1.00 | IDO1 (0.50) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL30910940 | 0.87 | CES2 (0.43) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL30986702 | 0.87 | CES2 (0.43) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL6566037 | 0.87 | CES2 (0.43) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL30057873 | 0.85 | CES2 (0.52) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL1902230 | 0.85 | CES2 (0.52) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL21831230 | 0.85 | CES2 (0.47) | IDO1TDO2GAAMEN1KMT2A | |
| SCHEMBL30910879 | 0.85 | CES2 (0.47) | IDO1TDO2GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665703-B1 | ENANTIOMER (R) OF LAUFLUMIDE IN MEHR ALS 95%ee | NLS PHARMA AG (CH) | 2017-12-06 | — | — | EP | claimed |
| EP-2665703-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | Assistance Publique Hôpitaux De Paris (FR) | 2013-11-27 | — | — | EP | claimed |
| US-20130295196-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) | 2013-11-07 | — | — | US | claimed |
| WO-2012098235-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2012-07-26 | — | — | WO | claimed |
| JP-5194293-A | — | — | None | — | — | JP | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| CN-110128233-B | Preparation method of deuterated alcohol compound | 南京工业大学 | 2021-02-02 | — | — | CN | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-0690051-B1 | DIAZACYCLOALKANEALKYLSULFONAMIDE DERIVATIVE | AZWELL INC (JP) | 2001-07-18 | — | — | EP | disclosed |
| US-5716950-A | NONTOXIC ANTIALLERGEN AND ANTIASTHMATIC HAVING LOW ANTIHISTAMINIC SIDE EFFECTS | NIPPON SHOJI KABUSHIKI KAISHA (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0690051-A1 | DIAZACYCLOALKANEALKYLSULFONAMIDE DERIVATIVE | NIPPON SHOJI KABUSHIKI KAISHA (JP) | 1996-01-03 | — | — | EP | disclosed |
| JP-H05194293-A | PREPARATION OF TERTIARY TRI-AND TETRAFLUOROPHENYLBENZYL ALCOHOLS | MERCK PATENT GMBH | 1993-08-03 | — | — | JP | disclosed |
| US-5077288-A | Adrenergic, serotonin and histamine antagonist | ADIR ET COMPAGNIE (FR) | 1991-12-31 | — | — | US | disclosed |
| US-4194049-A | 2-[[2-Methyl-1-[2-benzoyl(or benzyl)phenyl]-1H-imidazol-5-yl]methyl]-1H-isoindole-1,3(2H)-diones | HOFFMANN-LA ROCHE INC. (US) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885GAA 1984/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885GAA 1984/4885 |
| US-20130295196-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | HCRTR2, HNMT, CYP2U1 | IDO1 1302/4885TDO2 1053/4885GAA 25/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885GAA 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.